Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
|
|
- Shanon Shelton
- 5 years ago
- Views:
Transcription
1 Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1
2 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action 2
3 Pharmacy Trend Experience 3
4 Rx Drugs Source: Medicare-approved Drug Discount Cards and Prescription Drug Prices, Chisholm et al, Am J Health-Syst Pharm Vol 62, July 15,
5 MCHA Pharmacy Utilization PMPM $ $ $ $ Amt Paid PMPM $ $ Rx's PMPM $ $ $ $0.00 Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- 0 Amount Paid PMPM # Rx's PMPM 5
6 20 YTD MCHA Top Drug Report Cost Rank Medica BOB Cost Rank Brand Name Therapeutic Use # of Rx's Amount Paid by Plan % of Total Amt Paid Avg. Amt Paid/Rx Utilizing Members 1 1 LIPITOR High Cholesterol 10,539 $675, % $ ENBREL Rheumatoid Arthritis, Psoriasis 479 $593, % $1, EFFEXOR XR Depression 3,256 $381, % $ COPAXONE Multiple Sclerosis 257 $327, % $1, REYATAZ HIV/AIDS 496 $322, % $ PROTONIX GERD 3,027 $320, % $ ATRIPLA HIV/AIDS 292 $300, % $1, TRUVADA HIV/AIDS 463 $300, % $ PREVACID GERD 2,2 $281, % $ ADVAIR DISKUS COPD 2,036 $272, % $ LANTUS Diabetes 3,013 $270, % $ SEROQUEL Antipsychotic 1,483 $269, % $ HUMALOG Diabetes 2,294 $262, % $ LAMICTAL Anticonvulsant 1,254 $260, % $ EPZICOM HIV/AIDS 425 $257, % $ CELLCEPT Transplant Rejection 585 $248, % $ ACTOS Diabetes 1,863 $242, % $ CYMBALTA Depression 1,821 $221, % $ TOPAMAX Anticonvulsant 997 $215, % $ ONE TOUCH ULTRA TEST STRIPS Diabetes 2,493 $2, % $ KALETRA HIV/AIDS 366 $2, % $ LEXAPRO Depression 3,200 $197, % $ REBIF Multiple Sclerosis 129 $178, % $1, AVANDIA Diabetes 1,467 $168, % $ HUMIRA Rheumatoid Arthritis, Crohns 124 $165, % $1, Top 25 Drug Total 44,565 $7,146, Total Drug YTD 346,621 $19,529, Top 25 as a % of Total 12.86% 36.59% 6
7 $ Plan Paid Per Prescription $ $ $75.00 $50.00 $25.00 $0.00 Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- Brand Generic 7
8 MCHA Generic Utilization 60.00% 59.00% 58.00% 57.00% 56.00% 55.00% 54.00% 53.00% Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- De c- Jan- Feb- Mar- Apr- May- Jun- 8
9 Drug Trend 15.00% 10.00% 13.41% 9.00% % 7.90% 7.20% 5.00% 5.40% 4.87% 0.00% 2.80%2.90% 1.00% ESI* Medco+ Medica MCHA -5.00% -7.31% -5.00% % (Projected) Source: *ESI 2005, 20 Drug Trend Reports + Medco 2005, 20, 20 Drug Trend Reports 9
10 Trend Drivers and Management Opportunities 10
11 Introduction to Drug Trend Drivers Pharmacy Trend Drivers Member Contribution Price Utilization Mix What factors are within our control? Benefit Coverage Demographics 11
12 Introduction to Drug Trend Drivers Pharmacy Trend Drivers Member Contribution Price Utilization Mix Benefit Coverage Strategies used to address controllable influences Formulary management Clinical and trend management Plan design Demographics 12
13 Cost and Quality Asking tough questions Can we have it all and expect someone else to pay for it? Will medicine save us despite our unhealthy lifestyles? Should we pay for care that s not recommended by experts nor based on evidence? What defines medically necessary? 13
14 Cost and Quality Making Tough Decisions Formulary Management Preferred products Prior authorization medical necessity Generic incentives Clinical / Trend Management Step therapy: Use of a generic or low cost brand prior to a higher cost brand when medically appropriate. Quantity level limits: Supports benefit design, member cost share and prevents waste Disease and care management: Chronic condition coaching Plan Design Cost Share Network Restrictions Coverage exclusions or restrictions by category 14
15 Intervention Targets Members Physicians Pharmacists Generic incentives Formulary notifications Online self-service Disease education and management Specialty pharmacy services Wellness and lifestyle programs Formulary Interventions Pay for performance Generic samples Retrospective DUR Brand & generic substitution Therapeutic substitution On-line point-of-service edits 15
16 Impact of Managing the Formulary MCHA Statin Utilization Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- LIPITOR SIM VASTATIN VYTORIN CRESTOR LOV AST AT IN PRAVASTATIN SODIUM PRAVACHOL LESCOL LESCOL X L M EVACOR ZOCOR 16
17 A Call to Action 17
18 The Impact of Decision Making The True Cost of a Prescription Decision Nexium: $185 Prilosec OTC: $20 $165 per month NPV* = $17,172 The new math equation is: Prilosec OTC + = Nexium $17,172 * Net Present Value 18
19 The Obesity Burden 64%: Increase in diabetes patients, ,000%: Increase in obesity-related costs, $1,244: Annual health care spending difference, normal weight v. obese adults. Source: Health Affairs, June 2005 % of U.S. Health Spending On Obesity-linked Conditions 19
20 Specialty Pharmacy Cost 1 IMS Health, Company Reports and JP Morgan estimates 2 Ernst & Young, Competitive Growth, Growing Competition, Beyond Borders
21 MEDICA 21
Pharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationPrescription Benefit Management. Eric Cannon, PharmD, FAMCP
Prescription Benefit Management Eric Cannon, PharmD, FAMCP Agenda Drugs as a Share of Health Spending Top Drugs of 2016 Management Interventions and Strategies Specialty Pharmacy, Generics and Biologics
More informationJPMorgan Investor Meeting
David B. Snow, Jr. Chairman and CEO JoAnn A. Reed Senior Vice President, Finance and CFO Richard J. Rubino,, CPA Senior Vice President, Controller and CAO Robert S. Epstein, M.D., M.S. Senior Vice President,
More informationINSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
More informationSpring Understanding the potential of generic substitution
Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming
More informationCurators of the University of Missouri - Combined January 1, 2016 through December 31, 2016
Cost Management Report Delta Dental Network Coverage Network Utilization Discount Delta Dental PPO Network 28.3% 29.4% Delta Dental Premier Network 67.0% 12.0% Total 95.3% Savings Categories $ % of Net
More informationQ&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend
Learn More Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend Iowa and South Dakota Pharmacy Benefit Plans This document answers questions regardingupcoming
More informationUF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
More informationPrescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service
Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationJustifying New Oncology Pharmacist Positions
Faculty Disclosures Justifying New Oncology Pharmacist Positions I will not be discussing off-label uses of any medications I am on the speaker s bureau for Millenium Pharmaceuticals and am a paid consultant
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationCarisoprodolol Quantity Limit Policy Impact Analysis
Carisoprodolol Quantity Limit Policy Impact Analysis Carisoprodolol (Soma ) is a skeletal muscle relaxant that has deemed by many to have limited effectiveness for the treatment of acute musculoskeletal
More informationKansas EMS Naloxone (Narcan) Administration
Kansas EMS Naloxone (Narcan) Administration Executive Summary Kansas Board of Emergency Medical Services August 217 The following pages denote an ongoing trending of naloxone administration by Kansas Emergency
More informationAn Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center
An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center 1 TRICARE Eligible Beneficiaries Monthly Average, FY08 Retirees & Family
More informationThe power of partnership.
School Board of Clay County and UnitedHealthcare. Building health ownership together. December 13, 2017 Annual Healthplan Performance Review October 1, 2016 thru September 30, 2017 Let s get started inspiring
More informationThe Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist
The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving
More informationDRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationCurators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report
Cost Management Report Program Design Specifics Standard Claims Management SAVINGS CATEGORIES SAVINGS RESULTS % OF NET SUBMITTED DOLLARS % OF PAID DOLLARS Deductible Applied $1,296,627 5.68% 9.78% Patient
More informationPublished by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
More informationEducation around PML risk and monitoring at NHNN Queen Square MS Centre
Audit MS Masterclass, Sheffield, 31 st March 2017 Education around PML risk and monitoring at NHNN Queen Square MS Centre UCL Institute of Neurology Queen Square Multiple Sclerosis Centre National Hospital
More informationPharmacy Benefit Solutions 2010 Trend Report
Pharmacy Benefit Solutions 2010 Trend Report Here we share pharmacy benefit trend Presenting management our PBM performance trend performance the for the past past year year and a glimpse into the future.
More informationSelf-Insurance 2016 Q2 Update. Presented by Marcy Syman, Human Resources Director
Self-Insurance 2016 Q2 Update Presented by Marcy Syman, Human Resources Director Management Committee 9-12-2016 Dollars in Millions Self-Insured Plan Costs Q2 2016 (Claims, admin fees and stop loss premium)
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationNew York State Department of Health HIV Uninsured Care Programs
New York State Department of Health HIV Uninsured Care Programs AIDS Drug Assistance Program (ADAP) ADAP Plus (Ambulatory Care) HIV Home Care ADAP Plus Insurance Continuation (APIC) Lanny T. Cross Program
More informationDementia Content Report January Produced By The NHS Choices Reporting Team
Dementia Content Report January 2014 Produced By The NHS Choices Reporting Team CH.NHSChoices-Reporting@nhs.net Dementia Dashboard Page 1 Overall Choices Site Visits Tag cloud showing top dental related
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationUpdate to HMO Drug Formulary Tier Definitions. February 8, 2018
Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationDate : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark
Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationFGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS
AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021
More informationSpecialty conditions overview
Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year
More informationJan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X
Primary Prevention Breast Cancer Prevention Member: Mammography reminder letters to female members ages 51.5-74 who are overdue to get a mammogram Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Providers:
More informationCost-Effectiveness of Lung Volume Reduction Surgery
Cost-Effectiveness of Lung Volume Reduction Surgery The Health Industry Forum October 24, 2007 - Washington DC The National Emphysema Treatment Trial National Emphysema Treatment Trial (NETT) Multicenter,
More informationJOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
More informationEvaluation of Specialty Pharmacy in an Integrated Health-System
Evaluation of Specialty Pharmacy in an Integrated Health-System Emma Chermely, PharmD, BCACP Alyssa McCann, PharmD, BCACP *The presenters have no conflicts of interest to disclose. Objectives Introduce
More informationAn Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
More informationConversion of crestor to lipitor
Conversion of crestor to lipitor Apr 25, 2018. Atorvastatin (Lipitor ): 10 mg, Fluvastatin (Lescol ): 80 mg, Rosuvastatin. Nov 16, 2011. In a head-to-head test of two popular cholesterol-lowering statin
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More information$"% & '( ) " * +, !"##!""$ !*$-!+*" % $&
! """# # $"% & '( ')&# '( ) " * +, '( )(*!*$-!+*"!"##!""$ % $& &. / 011 12 ' 32 3 456 3. 3 0 11 32! 71 829:1 1' 3,3 12/ 2 31:181' 337)1 / 111 3 : 39.21)2 231 1 1 13' 223 333 23) 3;3 2 1 1' 11 3 31 333
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationPDF created with pdffactory trial version
We are using more prescription drugs than ever before to manage health conditions and prevent problems. And those drugs are more expensive than ever before. In 2003, prescription drug costs in the United
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationPositive Living Conference
Positive Living Conference Ft. Walton Beach, Thomas Liberti Chief, Bureau of HIV/AIDS Department of Health March 11, 2011 Tallahassee, 1 The Epidemic in, 2010 60% White Population: 18.8 million (4 th 16%
More informationSpecialty drugs are a significant cost trend driver for
2009 Drug Utilization and Cost Trends: Tumor Necrosis Factor Inhibitors Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; and John A. Szychowski, AAS, BS Specialty drugs are a significant
More informationSleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
More informationZegerid Capsules 20 mg and 40 mg Zegerid Powder for Oral Suspension 20 mg and 40 mg
Nasdaq: SNTS Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our management. The
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationF Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S
UNIVERSITY OF ALASKA F Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S Premera- Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm FY18
More informationColorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center
Colorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center Kaela Momtselidze Health Systems Manager Primary Care Systems American Cancer Society Sheri Frank Director of Corporate
More information2016 Drug Trend Report MEDICARE
2016 Drug Trend Report MEDICARE 2016 Drug Trend Report Medicare Introduction 3 Trend analysis 6 Keeping spending increases in check for America s seniors 7 Medicare Advantage Prescription Drug Plan (MAPD)
More informationCYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID
CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID BACKGROUND Cytokine and cell-adhesion molecule (CAM) antagonists have a major role in the treatment of chronic inflammatory diseases such
More informationF Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S
UNIVERSITY OF ALASKA F Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S Premera - Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm
More informationUsing Decision Support to Promote Value Based Prescribing
Using Decision Support to Promote Value Based Prescribing Session 218, February 14, 2019 Adam Szerencsy, DO Medical Director, Ambulatory Informatics NYU Langone Health 1 Conflict of Interest Adam Szerencsy,
More informationtaking at (Jan. 21, 2016) by Older 2016.pdf).
HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationCost projections a single antiretroviral co-payment scheme for people with HIV in NSW. March 2013
Cost projections a single antiretroviral co-payment scheme for people with HIV in NSW March 2013 Background The first meeting of HIV Strategy Implementation Taskforce Committee endorsed a policy position
More informationTRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE INTRODUCTION This Data Digest reports on changes in manufacturer prescription drug prices
More informationAlignment Strategies at the JPS Health Network
Improving the Patient Experience Alignment Strategies at the JPS Health Network JPS HEALTH NETWORK 537 bed hospital, Level 1 Trauma Center Tarrant County s Safety Net Hospital 15 primary care clinics 20
More informationIMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE Indiana Health and Wellness Summit
IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE 2018 Indiana Health and Wellness Summit National Diabetes Volunteer Leadership Council Who We Are Patient advocacy organization committed
More informationDisclosures. Learning Objectives 4/26/2017
Implementation of a quality improvement initiative to ensure the safe transition from prior-to-admission concentrated insulins to a formulary insulin regimen ERICA J. RHEIN, PHARMD PGY1 PHARMACY PRACTICE
More information4/2/2018. Easing the pharmacy experience and stretching the diabetes dollar. Alyson Blum, PharmD, CDE. I have no conflicts of interest to disclose
Easing the pharmacy experience and stretching the diabetes dollar. Alyson Blum, PharmD, CDE Clinical Pharmacist in Obstetrics Center for Maternal Fetal Medicine at Sacred Heart Medical Center Clinical
More informationSeasonality of influenza activity in Hong Kong and its association with meteorological variations
Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific
More informationGlobal Fund Approach to Health System Strengthening
Global Fund Approach to Health System Strengthening WHO Expert consultation on positive synergies between health systems and Global Health Initiatives Geneva, 29-30 May 2008 Dr Stefano Lazzari, Director
More informationMcLean ebasis plus TM
McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797
More informationThe use of high cost or Nonpreferred Brand drugs is contributing to higher overall costs for your group. Consider the following to reduce costs:
April 22, 2014 Sandy Randall Dear Ms. Randall: Enclosed are 4 th Quarter 2013 reports that analyze the major parameters of drug utilization by Rocky Mountain Health Plans (RMHP) Members within the. Graphs
More informationDispensing Patient- Speci/ic Insulin. Paul Parchesky, RPh Pharmacy Manager Newport Hospital November 1, 2014
Dispensing Patient- Speci/ic Insulin Paul Parchesky, RPh Pharmacy Manager Newport Hospital November 1, 2014 Goals Background on insulin dispensing at Newport Hospital Reasons for change Purchasing pacerns
More information18 Week 92% Open Pathway Recovery Plan and Backlog Clearance
18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted
More informationPRESCRIPTION DRUG TREND REPORT
EXPRESS SCRIPTS CANADA PRESCRIPTION DRUG TREND REPORT TRENDS IN CANADIAN PRIVATE DRUG SPEND Express Scripts Canada, 2018. All Rights Reserved TABLE OF CONTENTS EXECUTIVE SUMMARY... 3 METHODOLOGY AND TERMINOLOGY...
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationReducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital
Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell
More informationMassachusetts Department of Developmental Services. Medication Review
Massachusetts Department of Developmental Services Medication Review NASDDDS Reinventing Quality August 7, 2012 Alixe Bonardi 1, Gail Grossman 2 Emily Lauer 1 1 University of Massachusetts Medical School
More informationTri-County Opioid Safety Coalition Data Brief December 2017 Clackamas, Multnomah, and Washington Counties
Medicaid-Funded Alternative Treatment for Back Pain in the Tri-County Region Key Findings The percentage of members with a back pain diagnosis who received an alternative treatment increased from 29% in
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationAtorvastatin and upper arm pain
P ford residence southampton, ny Atorvastatin and upper arm pain Caduet (amlodipine and atorvastatin ) is used to treat high blood pressure or angina in patients with high cholesterol. Includes Caduet
More informationFAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?
FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members
More informationDesign, Implementation, and First-year Results of a Value-based Formulary
Design, Implementation, and First-year Results of a Value-based Formulary Watkins JW, Sullivan SD, Yeung K, Ramsey SD, Garrison LP, Wong E, Murphy C, Danielson D, Veenstra DL, Vogeler C, Burke W, McGee
More informationPBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.
Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences
More informationPharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
More information10/18/17. The Nuts and Bolts of an Integrative Pain Management Practice
The Nuts and Bolts of an Integrative Pain Management Practice Integrative Modalities and the Evidence that Supports them Robert Bonakdar, MD, FACN Selecting the Appropriate Arrow in Your Quiver Matching
More informationSolution for Consideration: Medical Tourism and Personal Rx Importation
Solution for Consideration: Medical Tourism and Personal Rx Importation Agenda 1. Background information on the challenges posed by specialty prescriptions. 2. Medical Tourism; Clinical Pharma Travel Program
More informationWinter Holiday Suicide Myth Continues to be Reinforced in Press Annenberg Public Policy Center Study Finds
FOR IMMEDIATE RELEASE DATE: 8 December 2010 CONTACT: Dan Romer, 215-898-6776 (office); 610-202-7315 (cell) Winter Holiday Suicide Myth Continues to be Reinforced in Press Annenberg Public Policy Center
More informationpaint a realistic picture of your organization s health
plan analytics paint a realistic picture of your organization s health Impressionism has no place in your health care benefit plan. Arm yourself with the facts. Uses up-to-date client-specific data Clears
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationTexas Vendor Drug Program Specialty Drug List Process. February 2019
Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed
More informationSave on your drugs with HealthyRx
Save on your drugs with HealthyRx HealthyRx is a savings program offered through the UVa Hoo s Well program. It helps lower your costs on drugs for certain health conditions. Effective 4/1/17, you are
More informationMassachusetts Department of Developmental Services Medication Review
University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 8-7-2012 Massachusetts Department of Developmental Services Medication Review Alexandra
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationThe Impact of Clinical Decision Support (CDS) Tools on Catheter Associated Urinary Tract Infections (CAUTI) January 22, 2010.
4 th Annual NDNQI Conference The Impact of Clinical Decision Support (CDS) Tools on Catheter Associated Urinary Tract Infections (CAUTI) January 22, 2010 UPMC St Margaret Bonnie B. Anton, MN RN antonbb@upmc.edu
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationPREPARED BY THE CENTER FOR MEDICARE ADVOCACY, INC.
MEDICARE DRUG CARDS PROVE INCONSISTENT AND PROVIDE FEW DISCOUNTS FOR MEDICARE BENEFICIARIES TRYING TO REDUCE THE COST OF THE TEN MOST POPULAR BRAND-NAME DRUGS USED BY SENIORS PREPARED BY THE CENTER FOR
More informationImplementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016
Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationMedicaid Perspective
Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:
More informationData Visualization - Basics
Data Visualization - Basics The Visualization Process ACQUIRE PARSE FILTER MINE REPRESENT REFINE INTERACT Sales Data (US $ in thousands) Region Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Domestic
More information